Patents Assigned to Bayer Pharma Aktiengesellschaft
  • Patent number: 11180471
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: November 23, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Eloisa Jimenez Nunez, Jens Ackerstaff, Susanne Roehrig, Alexander Hillisch, Katharina Meier, Stefan Heitmeier, Adrian Tersteegen, Jan Stampfuss, Pascal Ellerbrock, Daniel Meibom, Dieter Lang
  • Patent number: 11166932
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 9, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Marquardt, Markus Follmann, Johannes-Peter Stasch
  • Patent number: 11149023
    Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 19, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Heiko Schirmer, Hanna Tinel
  • Publication number: 20210316017
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radio-nuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 14, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventor: Arne SCHOLZ
  • Patent number: 11123439
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: September 21, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
  • Patent number: 11096934
    Abstract: The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2?-fluoro-[1,1?-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 24, 2021
    Assignees: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: David B. Sykes, David Scadden, Timothy A. Lewis, Andreas Janzer, Hanna Meyer, Detlef Stöckigt
  • Publication number: 20210253573
    Abstract: The present invention covers a method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (“the compound of formula (I)” in the following) as well as intermediate compounds useful in the preparation of the compound of formula (I). The present invention also covers polymorphic form B of the compound of formula (I) with very high purity.
    Type: Application
    Filed: August 22, 2019
    Publication date: August 19, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Philipp RUBENBAUER, Hendricus Nicolaas Sebastiaan VAN DER HAAS, Sonja Elisabeth HOOGEVEEN, Matthijs Cornelis Maria VAN OERS, Reinerus Gerardus GIELING, Jeroen Alexander DEKKER
  • Patent number: 11091463
    Abstract: The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 17, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Anja Buchmueller, Hanna Tinel, Karoline Droebner, Thomas Mondritzki, Heiko Schirmer, Axel Kretschmer, Carsten Schmeck, Pierre Wasnaire, Hana Cernecka
  • Publication number: 20210246166
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: December 30, 2020
    Publication date: August 12, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald BIERER, Ingo FLAMME, Dmitry ZUBOV, Thomas NEUBAUER, Adrian TERSTEEGEN, Cathleen JUHL, Marie GLATZ, Jan DREHER, Simon HOLTON, Carsten TERJUNG, Lars BAUMANN, Thorsten POETHKO, Jiancheng XIONG, Yibo QIU
  • Publication number: 20210236504
    Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Application
    Filed: January 28, 2021
    Publication date: August 5, 2021
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILIP LIENAU, ULRIKE SACK, MARTIN LANGE
  • Publication number: 20210230284
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
  • Patent number: 11071788
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 27, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
  • Publication number: 20210220357
    Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fiber sensitization, and/or other pathological conditions associated with autonomic imbalance caused by increased chemoreceptor sensitivity, in particular for the treatment of breathing disorders, Cheyne Stokes respiration, central and obstructive sleep apnea, cardiovascular disease, hypertension, resistant hypertension, and heart failure, which are related to increased activity of P2X3 receptors.
    Type: Application
    Filed: May 14, 2019
    Publication date: July 22, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Lucas Hudson HOFMEISTER, Oliver Martin FISCHER
  • Publication number: 20210220358
    Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fibre sensitization, in particular for treatment and prophylaxis of Chronic Cough (CC), Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disorder (COPD), and asthma.
    Type: Application
    Filed: May 14, 2019
    Publication date: July 22, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Christian FRIEDRICH, Isabella GASHAW, Damian BROCKSCHNIEDER, Oliver Martin FISCHER
  • Patent number: 11046783
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 29, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Patent number: 11040035
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 22, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert Schmees, Ilona Gutcher, Horst Irlbacher, Benjamin Bader, Na Zhao, Michael Platten, Ulrike Röhn, Ludwig Zorn, Lars Röse, Detlef Stöckigt
  • Publication number: 20210179541
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Application
    Filed: November 26, 2018
    Publication date: June 17, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Peter FEY, Philipp RUBENBAUER, Kai LOVIS, Britta OLENIK, Julia KUSEL, Felix SPINDLER
  • Publication number: 20210163474
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 3, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Kai LOVIS, Winfried JOENTGEN
  • Patent number: 11001636
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: May 11, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Christoph Mahlert, Simone Greven, Stephan Märsch
  • Publication number: 20210128572
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: May 6, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Antje Margret WENGNER, Gerhard SIEMEISTER